Impact BioMedical Inc. IBO
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -57.14% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -57.14% | -- | -- | -- | -- |
| Cost of Revenue | 0.00% | -- | -- | -- | -- |
| Gross Profit | -66.67% | -- | -- | -- | -- |
| SG&A Expenses | -59.02% | 272.89% | -53.47% | -28.23% | 215.89% |
| Depreciation & Amortization | -1.39% | 0.71% | 2.51% | 2.49% | 3.23% |
| Other Operating Expenses | -44.17% | -41.74% | -36.28% | 142.22% | 900.00% |
| Total Operating Expenses | -39.22% | 127.33% | 33.14% | -14.29% | 85.30% |
| Operating Income | 39.12% | -126.63% | -32.34% | 15.88% | -84.19% |
| Income Before Tax | 95.12% | -78.72% | 109.80% | -134.78% | -1,523.53% |
| Income Tax Expenses | -- | -- | -7,918.18% | -- | -- |
| Earnings from Continuing Operations | 95.12% | -78.72% | 119.29% | -134.78% | -1,523.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -83.33% | -127.27% | -60.00% | -16.67% | 220.00% |
| Net Income | 95.13% | -80.51% | 119.35% | -134.61% | -1,513.72% |
| EBIT | 39.12% | -126.63% | -32.34% | 15.88% | -84.19% |
| EBITDA | 51.68% | -175.65% | 0.11% | 91.82% | -38.40% |
| EPS Basic | 99.45% | 79.80% | 102.48% | -132.68% | -1,223.84% |
| Normalized Basic EPS | 99.45% | 79.67% | 120.18% | -132.58% | -1,219.07% |
| EPS Diluted | 99.15% | 80.71% | 102.43% | -301.06% | -1,211.10% |
| Normalized Diluted EPS | 99.45% | 79.67% | 120.18% | -303.95% | -1,219.07% |
| Average Basic Shares Outstanding | 784.82% | 793.49% | 679.95% | 5.92% | 21.90% |
| Average Diluted Shares Outstanding | 784.82% | 793.49% | 679.95% | -83.08% | 21.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |